Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pfizer may have to pay more cash and top $105 bln to win AstraZeneca

Tue, 29th Apr 2014 13:59

* Initial 30 pct cash component too low for AZ investors

* Pfizer may give more cash but limited by UK domicile move

* "White knights" thin on ground, Amgen said not interested

By Ben Hirschler and Simon Jessop

LONDON, April 29 (Reuters) - U.S. drugmaker Pfizer will need to raise its bid for AstraZeneca to around$105-110 billion and increase the proportion of cash in theoffer to win its British rival, investors believe.

After showing his hand and pressuring his smaller competitoron Monday by disclosing two bid approaches, both of which wererebuffed, Pfizer CEO Ian Read has until May 26 to "put up orshut up" under UK takeover rules.

Importantly, after a jump in Pfizer shares, Read knows hehas the backing of many of his own shareholders, while thethreat of a counterbid does not appear imminent.

Read and his team will be using the time available toconsider how they can sweeten an offer made in January worth58.8 billion pounds ($98.8 billion), or 46.61 pounds a share,comprising 30 percent cash and 70 percent shares.

AstraZeneca said that offer fell "very significantly" shortand it specifically flagged the small cash component, whichwould leave investors exposed to the risks faced by Pfizer inexecuting an ambitious mega-merger.

So far, the British group has refused to talk to Pfizer -but it has not ruled out discussions altogether and one personclose to the company said the cash component of any fresh offerwould be key in determining if there was engagement in future.

Cash is uppermost in the minds of AstraZeneca shareholders,too.

"For it to move forward from here, they (Pfizer) need tofind a way of getting Astra management engaged and that feelslike it needs a specific value being applied to the group, andit needs the cash element to be higher," said Alastair Gunn ofJupiter Fund Management, which is a top-20 investor inAstraZeneca.

Analysts at Jefferies believe a deal could get done withPfizer offering a 50/50 split between cash and shares at a priceof at least 50 pounds a share.

Several investors contacted by Reuters confirmed they werelooking for 50 pounds a share or more, with Neil Veitch of SVMAsset Management predicting an agreed deal somewhere between 52and 53 pounds.

Because a key goal of the planned takeover is to get the taxadvantages of re-domiciling the enlarged group in Britain, thereis a limit to how much cash Pfizer can offer, since at least 20percent of its shareholders are required to be UK-based.

"We estimate Pfizer will need to issue a minimum of around$55 billion in shares to comfortably meet this requirement,"Jefferies said.

Based on the original 30 percent cash element, Moody'sanalyst Michael Levesque said Pfizer could fund the whole of thecash portion with offshore funds.

Pushing the cash element to 50 percent, however, wouldrequire taking on some incremental debt.

SORIOT CANVASSES INVESTORS

AstraZeneca CEO Pascal Soriot, whose efforts to revive thefirm's drug pipeline have proved a key draw for Pfizer, will nowbe canvassing the views of shareholders as a "priority", withmachinery in place for meetings with big and small investors,two people close to the company said.

Soriot and chairman Leif Johansson will also be weighingstrategic alternatives for the drugmaker, including thepotential spin-off of non-core therapy areas like infection andneuroscience, as well as possible acquisitions.

But "white knight" counterbidders ready to take on Pfizerare likely to be thin on the ground - not least because fewother companies would enjoy the same cost and tax benefits fromacquiring AstraZeneca as Pfizer.

Amgen is one player for whom an AstraZeneca dealmight make sense, since the two companies are co-developing anumber of drugs, but a person familiar with the U.S. biotechfirm said on Tuesday it was not interested in entering the fray.

French drugmaker Sanofi is another company withthe heft and M&A experience to consider intervening, yet its CEOChris Viehbacher said on Tuesday he planned to stick to smallerbolt-on acquisitions.

GlaxoSmithKline, the British company with arguablythe greatest potential to extract synergies from buyingAstraZeneca, has meanwhile said for several years it is notinterested in large deals.

($1 = 0.5950 British Pounds) (Additional reporting by Anjuli Davies; Editing by Mark Potter)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.